ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANAB AnaptysBio Inc

25.07
-0.40 (-1.57%)
May 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 190,839
Bid Price 15.00
Ask Price 34.07
News -
Day High 25.43

Low
13.36

52 Week Range

High
27.50

Day Low 24.51
Company Name Stock Ticker Symbol Market Type
AnaptysBio Inc ANAB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.40 -1.57% 25.07 16:00:19
Open Price Low Price High Price Close Price Prev Close
25.43 24.51 25.43 25.07 25.47
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,794 190,839 $ 25.01 $ 4,773,728 - 13.36 - 27.50
Last Trade Time Type Quantity Stock Price Currency
16:20:00 priorref 105 $ 25.07 USD

AnaptysBio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
671.22M 26.76M - 17.16M -163.62M -6.11 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AnaptysBio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ANAB Message Board. Create One! See More Posts on ANAB Message Board See More Message Board Posts

Historical ANAB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week26.1426.2223.2324.53286,258-1.07-4.09%
1 Month19.6127.0218.4923.34396,6895.4627.84%
3 Months25.2727.5018.4923.14375,127-0.20-0.79%
6 Months14.4127.5013.3622.19314,02810.6673.98%
1 Year18.6827.5013.3620.61275,3786.3934.21%
3 Years26.0037.8913.3623.67249,191-0.93-3.58%
5 Years71.8779.099.1623.14329,629-46.80-65.12%

AnaptysBio Description

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.